Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel
文献类型：期刊论文
| 作者 | Miao, Yun-qiu2,3; Chen, Ming-shu2,3; Zhou, Xin3; Guo, Lin-miao1,3; Zhu, Jing-jing3; Wang, Rui2; Zhang, Xin-xin1,3 ; Gan, Yong1,3
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-01-19 |
| 页码 | 9 |
| 关键词 | lung cancer antitumor chitosan oligosaccharide liposomes paclitaxel drug delivery nanomedicine |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-020-00594-0 |
| 通讯作者 | Wang, Rui(ellewang@163.com) ; Zhang, Xin-xin(xinxinzhang@simm.ac.cn) ; Gan, Yong(ygan@simm.ac.cn) |
| 英文摘要 | Lung cancer is one of the leading causes of cancer-related death worldwide. Various therapeutic failed in the effective treatment of the lung cancer due to their limited accumulation and exposure in tumors. In order to promote the chemotherapeutics delivery to lung tumor, we introduced chitosan oligosaccharide (CSO) modification on the liposomes. CSO conjugated Pluronic P123 polymers with different CSO grafting amounts, called as CP50 and CP20, were synthesized and used to prepare CSO modified liposomes (CP50-LSs and CP20-LSs). CP50-LSs and CP20-LSs displayed significantly enhanced cellular uptake in A549 cells in vitro as well as superior tumor accumulation in vivo compared with non-CSO modified liposomes (P-LSs). This phenomenon was related to the increased affinity between CSO modified liposomes and tumor cells following massive adsorption of collagen, which was highly expressed in lung tumors. In the A549 tumor-bearing mouse model, intravenous injection of paclitaxel (PTX)-loaded CP50-LSs every 3 days for 21 days resulted in optimal antitumor therapeutic performance with an inhibition rate of 86.4%. These results reveal that CSO modification provides promising applicability for nanomedicine design in the lung cancer treatment. |
| WOS关键词 | GOLD NANOPARTICLES ; CELLULAR UPTAKE ; SURFACE ; BIODISTRIBUTION ; PEGYLATION ; PROTEINS ; SYSTEMS |
| 资助项目 | National Natural Science Foundation of China[81973250] ; National Science and Technology Major Project[2018ZX09721002-003] ; National Key Research and Development Program of China[NBHY-2017-J1-3] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000608960700001 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296149]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Rui; Zhang, Xin-xin; Gan, Yong |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Miao, Yun-qiu,Chen, Ming-shu,Zhou, Xin,et al. Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel[J]. ACTA PHARMACOLOGICA SINICA,2021:9. |
| APA | Miao, Yun-qiu.,Chen, Ming-shu.,Zhou, Xin.,Guo, Lin-miao.,Zhu, Jing-jing.,...&Gan, Yong.(2021).Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel.ACTA PHARMACOLOGICA SINICA,9. |
| MLA | Miao, Yun-qiu,et al."Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel".ACTA PHARMACOLOGICA SINICA (2021):9. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。